JFS Wealth Advisors LLC Buys 166 Shares of Edwards Lifesciences Co. (NYSE:EW)

JFS Wealth Advisors LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 31.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 700 shares of the medical research company’s stock after buying an additional 166 shares during the period. JFS Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $46,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Park Avenue Securities LLC lifted its position in shares of Edwards Lifesciences by 0.5% during the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after acquiring an additional 108 shares in the last quarter. City State Bank raised its position in Edwards Lifesciences by 16.5% in the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after purchasing an additional 130 shares during the period. Choreo LLC increased its holdings in shares of Edwards Lifesciences by 4.1% in the first quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock worth $367,000 after buying an additional 153 shares during the period. Stableford Capital II LLC lifted its stake in shares of Edwards Lifesciences by 2.7% in the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock valued at $533,000 after acquiring an additional 159 shares during the last quarter. Finally, Purus Wealth Management LLC grew its position in Edwards Lifesciences by 5.2% during the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after acquiring an additional 160 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.8 %

NYSE EW opened at $67.54 on Friday. The stock has a market cap of $40.69 billion, a PE ratio of 9.75, a P/E/G ratio of 3.86 and a beta of 1.13. The stock’s 50 day moving average is $67.92 and its 200 day moving average is $77.69. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the firm posted $0.59 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. Research analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Activity

In related news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,250 shares of company stock worth $1,099,238. 1.29% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on EW. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Truist Financial cut their price objective on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Piper Sandler cut their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Baird R W lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.